Vascular and pigment work is the part of aesthetic medicine where device selection is determined most directly by patient population. A platform that performs well on facial telangiectasia may be poorly matched to a port wine stain, and a wavelength that suits pigmented lesions may be the wrong instrument for a deeper vessel. Buyers who select on brand or on headline power rather than on chromophore match end up treating a narrow slice of the patients who walk through the door, and referring clinicians notice and stop referring.

This guide covers how vascular and pigment platforms are specified, how to match wavelength and pulse duration to specific lesions, how platform types compare, and how to test and cost the options before committing.

Which Devices Use This Modality and Why

Vascular and pigment lasers are used across a range of lesions where the target absorbs energy selectively at a chosen wavelength.

The mechanism is selective absorption: haemoglobin absorbs strongly at certain wavelengths and melanin at others, so choosing the right wavelength and pulse duration concentrates energy in the target while sparing surrounding tissue.

Vascular platforms typically use wavelengths matched to haemoglobin absorption, with longer pulses favouring larger or deeper vessels and shorter pulses suited to small superficial ones. Pigment platforms use wavelengths matched to melanin, which is why the same device family can address pigmented lesions and, at shorter pulse durations, tattoo ink. Dual-wavelength platforms combine both capabilities, which is the common configuration in clinics that treat a mixed lesion population. The practical result is that a single device rarely covers every case, and the selection decision is about coverage rather than about finding one platform that does everything.

Clinics with dermatology involvement typically need broader coverage, including longer-wavelength options for deeper vessels and short-pulse capability for pigment. Purely aesthetic clinics often see a narrower range, dominated by facial redness and sun-related pigmentation, and can select accordingly.

Wavelength, Power and Pulse: The Specs That Change the Outcome

Four specifications decide lesion coverage: wavelength, pulse duration, spot size and cooling.

Wavelength determines which chromophore absorbs the energy, pulse duration determines how the target responds to that absorption, and the two must be matched to the lesion to avoid treating the wrong tissue.

For vascular work, shorter wavelengths interact strongly with superficial haemoglobin and suit small vessels, while longer wavelengths penetrate further and are typically selected for deeper or larger vessels; pulse duration is lengthened in step so the vessel is heated without rupturing surrounding tissue. For pigment work, wavelength selection depends on the lesion’s depth and colour, and pulse duration determines whether the target is fragmented or heated. Spot size affects how deeply energy reaches as well as how quickly an area is covered, and cooling protects the epidermis while allowing more energy to be delivered at depth.

Two practical points follow. First, coverage claims should be tested against named lesion types rather than accepted generically: a platform that treats facial telangiectasia well may be unsuitable for deeper vessels regardless of its output. Second, pulse duration flexibility is often more valuable than maximum fluence, because the clinical decision is usually about matching duration to vessel or pigment characteristics rather than about applying more energy.

Indications This Modality Handles Well, and Those It Does Not

These platforms handle superficial vascular lesions and many pigmented lesions well, and they are used for port wine stains and other vascular malformations under appropriate clinical management.

They handle very deep or large-calibre vessels, some pigmented lesions requiring histology, and lesions where the diagnosis is uncertain less well, and those cases should be managed accordingly.

What the modality does well: facial telangiectasia, diffuse redness, small superficial vessels, sun-related pigmentation, and lesion-specific pigment work where the target is identified correctly. Port wine stains and similar vascular malformations are treated with these platforms, and outcomes depend on lesion characteristics, patient age and the number of sessions undertaken, which is why management should be framed clinically rather than as a guaranteed clearance. What the modality does less well: lesions where the clinical diagnosis is uncertain, where biopsy would be more appropriate, or where the target lies beyond the reach of the wavelengths available.

This is the strongest argument for assessing case mix before purchase. A clinic whose referrals include vascular malformations needs the wavelength and pulse range those cases require; one treating facial redness can select a narrower, less costly platform without clinical penalty.

Platform Comparison Across Manufacturers

Vascular and pigment platforms divide into dual-wavelength systems combining a vascular and pigment path, single-purpose vascular platforms, and multi-application consoles offering one path within a broader treatment menu.

The differences that matter commercially are lesion coverage, pulse duration flexibility and delivery system economics.

Compare platforms on five verifiable measures: lesion coverage against your referrals, pulse duration range at usable fluences, delivery system condition and replacement economics, service access in your country, and second-hand liquidity. Because vascular and pigment work is referral-driven, the coverage question usually outweighs price: a platform that cannot treat the cases you receive will not earn regardless of how well it performs on easier lesions. Pre-owned units prepared through ALLWILL’s Smart Center inspection are documented against the serial number, and custom written warranty terms are confirmed in the quotation.

What to Verify in a Demo or Sample Test

A demonstration should establish coverage and consistency rather than maximum output.

Run the wavelengths and pulse durations you will use, inspect the pattern across the full spot, and time a realistic treatment including cooling management.

Five checks are worthwhile. First, run two wavelengths representative of your case mix and confirm delivered output matches the displayed setting, because unmeasured performance is the most common gap on pre-owned vascular platforms. Second, inspect the beam profile or spot uniformity, since uneven delivery concentrates effect and complicates dosing. Third, test a short and a long pulse duration at usable fluences and confirm the platform changes behaviour predictably. Fourth, time a realistic lesion area including cooling and any interval between passes. Fifth, ask for the delivery system’s condition report and confirm that replacement components remain available for the generation.

Running Costs, Consumables and Service Intervals

Running cost on these platforms is dominated by service and eventual delivery system replacement, with limited consumable turnover.

Because there is no high-turnover consumable, cost per treatment is essentially the amortised source and optics expense divided by the number of sessions delivered.

Model it in three parts. First, source and delivery life: convert remaining hours into sessions at your settings and place replacement cost at the exhaustion point. Second, optics and delivery components: budget inspection, alignment and eventual replacement, and confirm availability for the generation. Third, service: preventive maintenance on the recommended interval, adjusted for throughput, plus a contingency for one unplanned intervention across three to four years. Consumables are typically limited to interface items, eyewear and aftercare products.

Where more than one provider can service the platform, compare response time, whether optics measurement is included, whether components for that generation can be sourced, and how performance is verified after repair. ALLWILL runs its own Smart Center inspection and repair hub and works through MET-certified technicians and trainers, which matters where a single optics component can take a referral-driven treatment line offline.

Compliance and Operator Requirements

Compliance covers the device file, the treatment environment and the operator’s clinical competence in lesion assessment.

The file should contain the clearance reference for the model, the establishment details, the label matching the serial number, the instructions for use and current electrical safety, calibration and output records.

Laser products marketed in the United States are regulated under the federal performance standard for light-emitting products, set out in 21 CFR Part 1040, with clearances confirmable in the 510(k) premarket notification database and establishment details in the registration and listing database.

Two points are specific to this modality. First, lesion diagnosis and the decision to treat rather than refer is a clinical judgement that no equipment specification can substitute for, and it should be documented in the patient record. Second, eye protection and controlled-area arrangements must match the wavelength in use, and operator training should cover the specific wavelengths and pulse durations applied; the Laser Institute of America publishes reference material used for that purpose.

Matching the Modality to Your Case Mix

The right platform is the one whose wavelength and pulse range covers the lesions you actually receive.

Match the wavelength set to your referrals, pulse duration range to the vessel and pigment characteristics you treat, and delivery system economics to your session volume.

Begin by auditing referrals over the preceding year: which lesion types arrived, which you treated in house and which you referred elsewhere. That distribution defines the wavelength coverage you need, and it often reveals that the platform currently being considered would address only part of the case load. Then consider who will treat: vascular and pigment work rewards clinician experience, and a platform whose parameter range exceeds your clinicians’ comfort will be used conservatively, which limits both outcomes and referrals. Finally, check the economics: with limited consumable turnover, payback depends on session volume against amortised source costs, so a platform chosen for coverage that never arrives will not earn.

Confirm delivery system supply for the generation before purchase, because on these platforms the optics are the asset and their availability defines the platform’s remaining useful life.

Vascular and pigment platform selection is a coverage question before it is a price question. Audit your referrals, match wavelength and pulse range to them, verify delivered output on the unit you are buying, and the platform will support the practice you actually run.

Part of the Tattoo & Pigment Lasers guide.